


# Selected Innovative Medicines in Development as of April 14, 2026



# Oncology (1 of 3)

## **AKEEGA (niraparib/abiraterone)**

M1 Metastatic Castration-Sensitive Prostate Cancer (AMPLITUDE)

## **INLEXZO (gemcitabine intravesical delivery system)**

Non Muscle Invasive Bladder Cancer (SunRISe-1)

## **TECVAYLI (teclistamab)**

Multiple Myeloma 1-3PLs (MajesTEC-3)

## **Bleximenib**

Acute Myeloid Leukemia (cAMeLot-3)

## **erda-iDRS (erdafitinib intravesical delivery system)**

Non Muscle Invasive Bladder Cancer (MoonRISe-1)

## **ERLEADA (apalutamide)**

High Risk Prostate Cancer (PROTEUS)

## **JNJ-1900 (NBTXR3)**

Head and Neck Cancer Platinum Ineligible

## **ramantamig**

Multiple Myeloma

## **DARZALEX (daratumumab)**

Frontline multiple myeloma transplant ineligible (CEPHEUS)

## **RYBREVANT (amivantamab)**

Frontline Non Small Cell Lung Cancer in combination with chemotherapy (PAPILLON)

## **TECVAYLI (teclistamab)**

Relapsed Refractory Multiple Myeloma CD38 exposed (MajesTEC-9)

## **CARVYKTI (Ciltacabtagene autoleucel)**

Frontline Multiple Myeloma TNI (CARTITUDE-5)

## **erda-iDRS (erdafitinib intravesical delivery system)**

High Risk Non Muscle Invasive Bladder Cancer (MoonRISe-3)

## **INLEXZO (gemcitabine intravesical delivery system)**

Non Muscle Invasive Bladder Cancer BCG-naïve High Risk (SunRISe-3)

## **pasritamig**

Prostate Cancer

## **RYBREVANT (amivantamab)**

Colorectal Cancer (ORIGAMI-2)

## **IMBRUVICA (ibrutinib)**

Frontline Mantle Cell Lymphoma (Triangle)

## **TALVEY (talquetamab)**

Relapsed Refractory Multiple Myeloma A-CD38 Naïve (MonumentAL-3)

## **Bleximenib**

Newly Diagnosed AML, chemo ineligible in combination with Venetoclax and Azacitidine (cAMeLot-2)

## **CARVYKTI (Ciltacabtagene autoleucel)**

Frontline Multiple Myeloma Transplant Eligible vs ASCT (CARTITUDE-6)

## **ERLEADA (apalutamide)**

Localized Prostate Cancer (ATLAS)

## **INLEXZO (gemcitabine intravesical delivery system)**

High Risk Non Muscle Invasive Bladder Cancer BCG Experienced (SunRISe-5)

## **pasritamig**

Prostate Cancer IL

## **RYBREVANT (amivantamab)**

Colorectal Cancer 2L (ORIGAMI-3)

## Oncology (2 of 3)

### **RYBREVANT (amivantamab)**

Head and Neck Cancer (ORIGAMI-5)

### **TALVEY (talquetamab)**

TIE NDMM in combination with DR (MajesTEC-7)

### **bleximenib**

Relapsed Refractory Acute Myeloid Leukemia (cAMeLot-1)

### **RYBREVANT (amivantamab)**

Head and Neck Cancer (ORIGAMI-4)

### **JNJ-1493**

Hematological Malignancies

### **JNJ-2638**

Gastrointestinal Cancer

### **JNJ-4496**

Hematological Malignancies

### **JNJ-6143 (HLD-0915)**

Prostate Cancer

### **TALVEY + TECVAYLI**

Relapsed Refractory Multiple Myeloma CD38 exposed (MonumenTAL-6)

### **TECVAYLI (teclistamab)**

TE NDMM maintenance (MajesTEC-4)

### **JNJ-0683 (ARX788)**

Breast Cancer

### **TALVEY + TECVAYLI**

Relapsed Refractory Multiple Myeloma (RedirectT-1)

### **JNJ-1900 (NBTXR3)**

Head and Neck Cancer Platinum Eligible

### **JNJ-2761**

Multiple Myeloma

### **JNJ-4680**

Lung Cancer

### **JNJ-6692**

Hematological Malignancies

### **TALVEY (talquetamab)**

Relapsed Refractory Multiple Myeloma CD38 exposed (MonumenTAL-6)

### **TECVAYLI (teclistamab)**

TIE NDMM in combination with DR (MajesTEC-7)

### **JNJ-1900 (NBTXR3)**

Lung Cancer

### **JNJ-0387**

Solid Tumors

### **JNJ-2175**

Solid Tumors

### **JNJ-3413**

Lymphoma

### **JNJ-4916**

Lung Cancer

### **JNJ-7446**

Lung Cancer

## Oncology (3 of 3)

---

**JNJ-8177 (ARX517)**

Prostate Cancer

**JNJ-8377**

Lymphoma

**JNJ-9401**

Prostate Cancer

**JNJ-9530**

Hematological Malignancies

**JNJ-9892**

Hematological Malignancies

**JNJ-9968**

Hematological Malignancies

# Immunology (1 of 2)

## ICOTYDE (icotrokinra)

Psoriasis (ICONIC)

## STELARA (ustekinumab)

Pediatric Ulcerative Colitis (UNIFI JR)

## TREMFYA (guselkumab)

Pediatric Juvenile Psoriatic Arthritis

## nipocalimab

Sjogren's Disease

## TREMFYA (guselkumab)

Pediatric Crohn's Disease (MACARONI-23)

## JNJ-4804 Co-antibody Therapy

Ulcerative Colitis

## JNJ-5223

Psoriatic Arthritis

## nipocalimab

Systemic Lupus Erythematosus

## nipocalimab

Warm Autoimmune Hemolytic Anemia (ENERGY)

## STELARA (ustekinumab)

Pediatric Juvenile Psoriatic Arthritis

## icotrokinra

Ulcerative Colitis (ICONIC-UC)

## nipocalimab

Hemolytic Disease of the Fetus and Newborn (AZALEA)

## TREMFYA (guselkumab)

Pediatric Ulcerative Colitis (QUASAR JR)

## JNJ-4804 Co-antibody Therapy

Psoriatic Arthritis

## JNJ-5939

Atopic Dermatitis

## nipocalimab

Idiopathic Inflammatory Myopathy

## STELARA (ustekinumab)

Pediatric Crohn's Disease (UNITI JR)

## TREMFYA (guselkumab)

Psoriatic Arthritis Structural Damage (APEX)

## icotrokinra

Psoriatic Arthritis (ICONIC-PsA)

## nipocalimab

Fetal and Neonatal Alloimmune Thrombocytopenia (FREESIA)

## icotrokinra

Crohn's Disease (ICONIC-CD)

## JNJ-4804 Co-antibody Therapy

Crohn's Disease

## JNJ-7528

Atopic Dermatitis

## JNJ-5108

Immunological Diseases

**JNJ-6848**

Immunological Diseases

**JNJ-8638**

Immunological Diseases

# Neuroscience

---

## **CAPLYTA (lumateperone)**

Adjunctive Treatment for Major Depressive Disorder

## **nipocalimab**

Chronic Inflammatory Demyelinating Polyneuropathy (ARISE)

## **SPRAVATO (esketamine)**

Major Depressive Disorder with Suicidal Ideation  
Pediatrics

## **ITI-1284**

Alzheimer's Disease-Related Agitation

## **JNJ-5120**

Major Depressive Disorder

## **CAPLYTA (lumateperone)**

Bipolar Mania

## **RPGR Gene Therapy**

Retinitis Pigmentosa (LUMEOS)

## **ITI-1284**

Generalized Anxiety Disorder

## **JNJ-1887 sCD59**

Geographic Atrophy

## **CAPLYTA (lumateperone)**

Pediatric Psychiatric Indications

## **seltorexant**

Adjunctive Treatment for Major Depressive Disorder with  
Insomnia Symptoms (OARS)

## **ITI-1284**

Alzheimer's Disease-Related Psychosis

## **JNJ-2056 (tau active immunotherapy) \***

Alzheimer's Disease (RETAIN)

## Select Other Areas

---

### CABENUVA

HIV Adolescents

### milvexian (Factor Xla)

Secondary Stroke Prevention

### SIRTURO

Tuberculosis Long Acting

### UPTRAVI (selexipag)

Pediatric Pulmonary Arterial Hypertension (SALTO)

### milvexian (Factor Xla)

Atrial Fibrillation

### macitentan

Pulmonary Arterial Hypertension 75mg (UNISUS)

### SIRTURO

Leprosy

\*This is not a fully exhaustive list of all pipeline programs and assets. The pipeline includes assets currently progressing through clinical trials as well as those under review by regulatory bodies. Inclusion in the pipeline is based on the current status of these programs and assets and does not guarantee continued investment. This information is as of April 14, 2026 to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information. \*AC Immune ACI-35.030. Strategic Partnerships, Collaborations, and Licensing arrangements -milvexian: Bristol Myers Squibb; AAV-RPGR: UCL Business Plc; JNJ-1887: Hemera Biosciences; Long acting HIV injectible treatment regimen of rilpivirine and cabotegravir: ViiV Healthcare; REMICADE and SIMPONI/SIMPONIA: Schering-Plough (Ireland) Company, a subsidiary of Merck & Co., Inc. and Mitsubishi Tanabe Pharma Corporation; TREMFYA: MorphoSys AG; JNJ-2113: Protagonist Therapeutics; Tau Immunotherapy: AC Immune SA; IMBRUVICA: Pharmacyclics, LLC, an AbbVie company; ZYTIGA: BTG International; DARZALEX and DARZALEX FASPRO: Genmab A/S; ERLEADA: Regents of California and Memorial Sloan Kettering; CARVYKTI: Legend Biotech; AKEEGA: TESARO, an oncology-focused business within GSK; lazertinib: Yuhan Corporation; Duobody Platform bispecific antibody programs: Genmab A/S; ENHANZE platform; Halozyme Therapeutics; XmAb CD28 bispecific antibodies; Xencor; iPSC-derived chimeric antigen receptor (CAR) NK and CAR T-cell product candidates: Fate Therapeutics; UPTRAVI and OPSUMIT: Nippon Shinyaku (co-promotion in Japan); CD20-directed autologous CAR-Ts: Cellular Biomedicine Group, Inc. (CBMG); muscarinic M1 receptor antagonist: Pipeline Therapeutics; NBTXR3: Nanobiotix; A2a Receptor Antagonist: AdoRx Therapeutics Limited